RAPIVAB FDA Approved December 2014
BioCryst Pharmaceuticals designs, optimizes and develops novel small-molecule drugs that block key enzymes to treat rare diseases.
BioCryst's core development programs include BCX7353 and other 2nd generation oral inhibitors of plasma kallikrein for hereditary angioedema and BCX4430, a broad spectrum antiviral for hemorrhagic fevers.
Learn more about BioCryst’s broad spectrum antiviral BCX4430, a potential medical countermeasure for filoviruses.
February 15, 2017
January 30, 2017
Year end 2016 results & corporate update Feb 27, 2017